All relevant data are available in the manuscript.

Introduction {#sec005}
============

Metabolic syndrome (MetS) is comprised of a group of risk factors for type 2 diabetes and cardiovascular diseases, including insulin resistance, abdominal obesity, dyslipidemia, blood pressure, and impaired fasting glucose\[[@pone.0170361.ref001]\]. The most common clinical manifestations of MetS include: abdominal obesity, hypertriglyceridaemia, reduced high-density lipoprotein cholesterol (HDL-C), hyperglycaemia, and high blood pressure (BP)\[[@pone.0170361.ref002]\]. MetS is responsible for a three-fold increase in the risk of atherosclerotic cardiovascular diseases (CVDs) and increased mortality from CVD, as well as all-causes, compared to the general population \[[@pone.0170361.ref003]\]. MetS is also associated with a fourfold increased relative risk of developing diabetes \[[@pone.0170361.ref004], [@pone.0170361.ref005]\]. There are eight commonly used definitions for MetS, but the National Cholesterol Education Programme-Adult Treatment Panel III (NCEP ATP III) and the International Diabetes Federation (IDF) definitions are the most commonly used \[[@pone.0170361.ref006]\]. These definitions have many similarities, but they differ on several components and on the cut-off points used ([Table 1](#pone.0170361.t001){ref-type="table"}).

10.1371/journal.pone.0170361.t001

###### Summary of the MetS definitions.

![](pone.0170361.t001){#pone.0170361.t001g}

  Definitions                                         WHO                                                                    NCEP-ATP III                                                                      IDF                                                                               EGIR                                   AACE                                                                              AHA/NHLBI                                                           ATP III                                                             JS 2009
  --------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------------- --------------------------------------------------------------------------------- -------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------------------
  **Number of Criteria**                              Two or more of:                                                        Three or more of:                                                                 Two or more of                                                                    Two or more of:                        Obesity and two or more of:                                                       Three or more of:                                                   Three or more of:                                                   Three or more of:
  **Obesity**                                         BMI \> 30 and/or WHR \> 0.9 (men), WHR \> 0.85 (women)                 WC ≥ 102 cm (men), WC ≥ 88 cm (women                                              WC ≥ 94 cm men, WC ≥ 80 cm women                                                  WC ≥ 94 cm (men, WC ≥80 cm (women)     WC ≥ 102 cm (men), WC ≥ 88 cm (women                                              BMI ≥ 30 kg/m2                                                      WC ≥ 102 cm (men), WC ≥ 88 cm (women                                Population- and country-specific definitions
  **Blood pressure mmhg**                             ≥ 140/90                                                               ≥ 130/85 or treatment                                                             ≥130/≥85 or treatment                                                             ≥ 140/90                               ≥ 130/85 or treatment                                                             ≥130/85 mmHg or previous hypertension diagnosis                     ≥ 130/85 or treatment                                               ≥ 130/85 or treatment
  **Dyslipidmia:**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  **HDL-C**                                           ≥ 35 mg/dL (0.9 mmol/L) in men or ≥ 39 mg/dL (≥ 1.0 mmol/L) in women   ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment   ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment   ≥ 39 mg/dL (1.0 mmol/L) or treatment   ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment   ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women   ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women   ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment
  **Triglycerides**                                   ≥178 mg/dL(2.0 mmol/L) or treatment                                    ≥150 mg/dL (1.7 mmol/L) or treatment                                              ≥150 mg/dL (1.7 mmol/L) or treatment                                              ≥150 mg/dL (1.7 mmol/L)                ≥150 mg/dL (1.7 mmol/L) or treatment                                              ≥150 mg/dL (1.7 mmol/L) or treatment                                ≥150 mg/dL (1.7 mmol/L)                                             ≥150 mg/dL (1.7 mmol/L) or treatment
  **Glucose Intolerance or Fasting Plasma Glucose**   ≥110 mg/dL (6.1 mmol/l), DM, IGT, IR                                   ≥100 mg/dL (5.6 mmol/L) or T2D                                                    ≥100 mg/dL (5.6 mmol/L) or T2D                                                    ≥110 mg/dL (6.1 mmol/L)                ≥110 mg/dL (6.1 mmol/l), or treatment                                             ≥100 mg/dL (5.6 mmol/L) or T2D                                      ≥110 mg/dL (6.1 mmol/L)                                             ≥100 mg/dL (5.6 mmol/L) or T2D

BMI = body mass index; JC = Joint Consensus; DM = diabetes mellitus; EGIR = European Group against Insulin Resistance; HDL-C = high-density lipoprotein cholesterol; IDF = International Diabetes Federation; IGT = impaired glucose tolerance; IR = insulin resistance; NCEP ATPIII = National Cholesterol Education Program Adult Treatment Panel; AACE = American Association of Clinical Endocrinologists; AHA/NHLBI = The American Heart Association / National Heart, Lung, and Blood Institute; JS = Joint Statement; T2 D, type II diabetes mellitus; WC = waist circumference; WHO = World Health Organization; WHR = waist hip ratio.

Therefore, although we could expect slight differences in prevalence rates, according to the criteria used in each study, genetic and geographical differences may also contribute to differences in the rates of MetS. For example, using the ATP III definition, Ford et al. reported the prevalence rate of metabolic syndrome in the USA to be 34.3% \[[@pone.0170361.ref003]\], while Tillin et al. reported the age-adjusted rates were 18.4% for men and 14.4% for women among Europeans, 28.8% for men and 31.8% for women in South Asians, and 15.5% for men and 23.4% for women in African-Caribbeans. Further, the prevalence rate was reported to be 15.7% in Taiwan, using the same criteria\[[@pone.0170361.ref007], [@pone.0170361.ref008]\].

Rheumatoid arthritis (RA) is a chronic inflammatory disorder of unknown etiology \[[@pone.0170361.ref009]\] that has a prevalence rate of approximately 0.5 to 1% \[[@pone.0170361.ref010]\]. Rheumatoid arthritis and metabolic syndrome are considered to be diseases with common traits that can increase the risk of cardiovascular disease\[[@pone.0170361.ref011]\], with previous research showing an association between the two\[[@pone.0170361.ref012]\]. Higher frequencies of insulin resistance and MetS have been reported in patients with RA \[[@pone.0170361.ref012], [@pone.0170361.ref013]\], with the frequency of MetS in RA patients ranging from 14 to 56% \[[@pone.0170361.ref014]\]. This variation can be explained by differences in the definition of MetS, along with differences in ethnicity, geographic area, study design, and study population. However, although many studies have reported a higher prevalence of MetS among RA patients, compared to the general population \[[@pone.0170361.ref015], [@pone.0170361.ref016]\], a number of studies have reported a higher prevalence of MetS in the healthy controls \[[@pone.0170361.ref002]\].

Research measuring the prevalence of MetS in RA patients has resulted in a wide range of estimates across the world. In addition, research measuring the prevalence of metabolic syndrome using a large sample size is rare. Furthermore, there have been very few meta-analyses on the prevalence of MetS in patients with rheumatoid arthritis \[[@pone.0170361.ref011]\]. Therefore, the present study aimed to: 1) determine the prevalence of MetS, and its components, in RA patients across the world 2) update the odds ratio of MetS in RA patients, compared to healthy controls, using a comprehensive systematic review and meta-analysis.

Methods {#sec006}
=======

Search strategy and study selection {#sec007}
-----------------------------------

The current systematic review and meta-analysis was conducted according to PRISMA guidelines \[[@pone.0170361.ref017]\]. A systematic review was undertaken of English-language medical literature published between January 2000 and August 2016 to identify scientific papers reporting the prevalence and risk of metabolic syndrome and its components (i.e., waist circumference---WC, blood pressure---BP, high-density lipoprotein cholesterol -HDL-C, Triglycerides---TG, fasting blood sugar---FBS) among rheumatoid arthritis patients.

International databases, including: the Web of Science, Medline, Scopus, Embase, CABI, CINAHL, DOAJ, Index Medicus for Eastern Mediterranean Region-IMEMR and Google Scholar were searched using the following medical subject headings (MeSH): "Metabolic Syndrome", "Dysmetabolic Syndrome", "Cardiovascular Syndrome", and "Insulin Resistance Syndrome", combined with "Rheumatoid Arthritis", "Prevalence", "Odds Ratio", "Comparative Cross-sectional Studies" and "case-control studies". The search strategy for Medline was developed first and then adapted for the remaining databases. More detailed information regarding the search strategy is presented in [Box 1](#pone.0170361.box001){ref-type="boxed-text"}. The grey literature were searched using Google Scholar, as recommended \[[@pone.0170361.ref018]\], using the abovementioned search strategy. An expert in this field was also consulted to identify additional papers.

### Box 1. Search strategy for MEDLINE (MeSH, Medical Subject Headings). {#sec008}

1: Metabolic Syndrome \[Text Word\] OR Metabolic Syndrome \[MeSH Terms\]

2: Dysmetabolic Syndrome \[Text Word\] OR Dysmetabolic Syndrome \[MeSH Terms\]

3: Cardiovascular Syndrome \[Text Word\] OR Cardiovascular Syndrome \[MeSH Terms\]

4: Insulin Resistance Syndrome \[Text Word\] OR Insulin Resistance Syndrome \[MeSH Terms\]

5: 1 OR 2 OR 3 OR 4

6: Rheumatoid Arthritis \[Text Word\] OR Rheumatoid Arthritis \[MeSH Terms\]

7: 5 AND 6

8: Prevalence \[Text Word\] OR Prevalence \[MeSH Terms\]

9: Odds Ratio \[Text Word\] OR Odds Ratio \[MeSH Terms\]

10: Risk Ratio \[Text Word\] OR Risk Ratio \[MeSH Terms\]

11: Cross-Product Ratio \[Text Word\] OR Cross-Product Ratio \[MeSH Terms\]

12: 8 OR 9 OR 10 OR 11

13: Cross-sectional Studies \[Text Word\] OR Cross-sectional Studies \[MeSH Terms\]

14: Case-Control Studies \[Text Word\] OR Case-Control Studies \[MeSH Terms\]

15: Comparative cross-sectional Studies \[Text Word\] OR Comparative cross-sectional Studies \[MeSH Terms\]

16: 13 OR 14 OR 15

17: 7 AND 12 AND 16

All publications were categorized using Endnote X6. The title and abstract of identified publications were systematically screened and full texts were obtained for those which passed the initial screening. All full text publications were then independently evaluated by two reviewers (SS and JH) for inclusion in the review. Disagreements between the reviewers were resolved by consensus using a third expert (MN). In this study, blinding and task separation were also applied to study selection.

All English language observational (cross-sectional and comparative cross-sectional) studies on the prevalence of metabolic syndrome were included in the current study if they clearly described the date of data collection and study location, used appropriate sampling strategies, and conducted appropriate statistical analyses. Case studies and letters to the editor were excluded, along with systematic reviews or meta-analyses. Lastly, studies undertaken on patients with other disorders were also excluded.

Data extraction and quality assessment {#sec009}
--------------------------------------

Study characteristics (first author's name, date of publication, and country of origin), participant characteristics (gender, age, and sample size), and MetS prevalence (based on the different criteria) were extracted using the full text reviews. The quality of each included study was also assessed using the STROBE checklist \[[@pone.0170361.ref019]\].

Statistical analysis {#sec010}
--------------------

All statistical analyses were undertaken using Review Manager (RevMan) Version 5.3. (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). The prevalence of metabolic syndrome, and its five components, among rheumatoid arthritis patients were pooled using a random-effects model and presented in a forest plot. The odds ratios for metabolic syndrome in rheumatoid arthritis patients, based upon the different diagnostic criteria, in comparative cross-sectional studies were also pooled using a random-effects model and presented in a forest plot. Statistical heterogeneity was assessed using the I^2^ index and a random-effects model was used when the I^2^ index was \> 0.6. Stata software version 13 (Stata Corp, College Station, TX, USA) was used to determine which factors were responsible for any observed heterogeneity using meta-regression. Publication bias, with regards to the ORs between MetS and RA was assessed using a Funnel plot and Begg\'s correlation test \[[@pone.0170361.ref020]\].

Results {#sec011}
=======

After removing duplicates, our primary search found 237 relevant articles. Following the exclusion of all non-eligible studies a total of 70 cross-sectional studies and 43 comparative cross-sectional studies, from 25 countries, were retained to estimate the prevalence and risk of metabolic syndrome among RA patients. The details of our study selection method are shown in [Fig 1](#pone.0170361.g001){ref-type="fig"}. The majority of the studies reporting MetS prevalence (55 studies) included both male and female patients who were aged \>18 years. The lowest and highest prevalence of MetS in rheumatoid arthritis patients reported were 10.6% and 55.5%, respectively. More detailed information about each included studies can be found in [Table 2](#pone.0170361.t002){ref-type="table"}.

![Flow diagram of the study selection process.](pone.0170361.g001){#pone.0170361.g001}

10.1371/journal.pone.0170361.t002

###### Worldwide prevalence (95% CI) of metabolic syndrome in rheumatoid arthritis patients.

![](pone.0170361.t002){#pone.0170361.t002g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author      Country        Criteria            DOP    Age Range    Mean Age   Gender   N. of RA Patients   Prevalence of MetS in RA Patients (%)   Reference                           
  ----------------- -------------- ------------------- ------ ------------ ---------- -------- ------------------- --------------------------------------- ----------- ------- ------- ------- -----------------------------
  Lee SH            Korea          AHA/NHLBI           2016   ≥12          63.6       Both     598                 110                                     488         36.4    34.5    36.9    \[[@pone.0170361.ref037]\]

  Hugo M            France         IDF                 2016   18--75       57.6       Both     57                  15                                      42          24.0    25.0    24.0    \[[@pone.0170361.ref038]\]

  Zafar ZA          Pakistan       NCEP-ATP III        2016   20--60       43.8       Both     384                 97                                      277         31.3    18.5    35.5    \[[@pone.0170361.ref035]\]

  Oliveira BMGB     Brazil         NCEP-ATP III        2016   \-           55.5       Female   107                 \-                                      107         51.4    \-      51.4    \[[@pone.0170361.ref024]\]

  Oliveira BMGB     Brazil         IDF                 2016   \-           55.5       Female   107                 \-                                      107         53.4    \-      53.4    \[[@pone.0170361.ref024]\]

  Muller R          Estonia        NCEP-ATP III        2016   \-           51.6       Both     91                  66                                      25          35                      \[[@pone.0170361.ref033]\]

  Dihingia P        India          NCEP-ATP III        2016   \>12         41.5       Both     72                  6                                       66          16.7                    \[[@pone.0170361.ref039]\]

  Ghazaly AHAH      Egypt          ATP III             2015   ≥18          40.7       Both     80                  13                                      67          50.0    53.8    49.2    \[[@pone.0170361.ref040]\]

  Salamon L         Croatia        ATP III             2015   52--68       59         Both     583                 100                                     483         43.1    40.0    43.7    \[[@pone.0170361.ref041]\]

  Tanayakom P       Thailand       NCEP-ATP III        2015   \-           59         Both     267                 31                                      236         16.1    12.9    16.5    \[[@pone.0170361.ref042]\]

  Parra-Salcedo F   Mexico         AHA/NHLBI           2015   \-           38.1       Both     160                 18                                      142         28.0                    \[[@pone.0170361.ref043]\]

  Parra-Salcedo F   Mexico         IDF                 2015   \-           38.1       Both     160                 18                                      142         18.0                    \[[@pone.0170361.ref043]\]

  Parra-Salcedo F   Mexico         NCEP-ATP III        2015   \-           38.1       Both     160                 18                                      142         24.0                    \[[@pone.0170361.ref043]\]

  Craciun L         Romania        IDF-AHA             2014   32--79       55.2       Both     51                  7                                       77          19.0    10.52   82.47   \[[@pone.0170361.ref023]\]

  Craciun L         Romania        NCEP-ATP III        2014   32--79       55.2       Both     51                  7                                       77          23.0                    \[[@pone.0170361.ref023]\]

  Craciun L         Romania        IDF                 2014   32--79       55.2       Both     51                  7                                       77          18.0                    \[[@pone.0170361.ref023]\]

  Craciun L         Romania        AHA                 2014   32--79       55.2       Both     51                  7                                       77          14.0                    \[[@pone.0170361.ref023]\]

  Bilecik NA        Turkey         IDF                 2014   24--65       52.0       Female   100                 \-                                      100         33.0    \-      33.0    \[[@pone.0170361.ref044]\]

  Bilecik NA        Turkey         NCEP-ATP III        2014   24--65       52.0       Female   100                 \-                                      100         27.0    \-      27.0    \[[@pone.0170361.ref044]\]

  Özmen M           Turkey         NCEP-ATP III        2014   \-           51.0       Both     52                  15                                      37          17.30                   \[[@pone.0170361.ref045]\]

  Özmen M           Turkey         WHO                 2014   \-           51.0       Both     52                  15                                      37          28.80                   \[[@pone.0170361.ref045]\]

  Kumar BS          India          IDF                 2014   ≥18          46.0       Both     54                  6                                       48          29.0                    \[[@pone.0170361.ref046]\]

  Kumar BS          India          NCEP-ATP III        2014   ≥18          46.0       Both     54                  6                                       48          31.0                    \[[@pone.0170361.ref046]\]

  Abourazzak FE     Morocco        IDF                 2014   \>16         49.0       Both     179                 22                                      157         30.7                    \[[@pone.0170361.ref026]\]

  Abourazzak FE     Morocco        NCEP-ATP III        2014   \>16         49.0       Both     179                 22                                      157         29.0                    \[[@pone.0170361.ref026]\]

  Abourazzak FE     Morocco        AACE 2003           2014   \>16         49.0       Both     179                 22                                      157         24.6                    \[[@pone.0170361.ref026]\]

  Salinas MJH       Argentina      ATP III             2013   \-           55.5       Both     409                 69                                      340         30.0    62.0    23.8    \[[@pone.0170361.ref047]\]

  Salinas MJH       Argentina      IDF                 2013   \-           55.5       Both     409                 69                                      340         35.0                    \[[@pone.0170361.ref047]\]

  Abdul-Qahar       Iraq           NCEP-ATP III        2013   \-           46.9       Both     203                 41                                      162         51.2    12.0    92.0    \[[@pone.0170361.ref048]\]

  Rostam S          Morocco        NCEP-ATP III-2004   2013   \-           49.0       Both     120                 10                                      110         30.8    10.0    32.7    \[[@pone.0170361.ref049]\]

  Rostam S          Morocco        NCEP-ATP III-2001   2013   \-           49.0       Both     120                 10                                      110         24.6                    \[[@pone.0170361.ref049]\]

  Rostam S          Morocco        WHO                 2013   \-           49.0       Both     120                 10                                      110         20.0                    \[[@pone.0170361.ref049]\]

  Rostam S          Morocco        IDF                 2013   \-           49.0       Both     120                 10                                      110         48.6                    \[[@pone.0170361.ref049]\]

  Rostam S          Morocco        EGIR                2013   \-           49.0       Both     120                 10                                      110         18.0                    \[[@pone.0170361.ref049]\]

  Rostam S          Morocco        JC 2009             2013   \-           49.0       Both     120                 10                                      110         32.3                    \[[@pone.0170361.ref049]\]

  Lee SG            Korea          NCEP-ATP III        2013   22--76       50.6       Female   84                  \-                                      84          19.0    \-      19.0    \[[@pone.0170361.ref034]\]

  Ormseth MJ        USA            ATP III             2013   ≥18          54.0       Both     162                 18                                      144         36.0                    \[[@pone.0170361.ref050]\]

  Karakoc           Turkey         IDF                 2012   \-           49.8       Both     54                  7                                       47          42.6                    \[[@pone.0170361.ref051]\]

  Manka V           Slovakia       IDF                 2012   ≥18          58.8       Both     87                  4                                       83          48.3                    \[[@pone.0170361.ref052]\]

  Manka V           Slovakia       NCEP-ATP III        2012   ≥18          58.8       Both     87                  4                                       83          44.8                    \[[@pone.0170361.ref052]\]

  Manka V           Slovakia       AHA/NHLBI           2012   ≥18          58.8       Both     87                  4                                       83          47.1                    \[[@pone.0170361.ref052]\]

  Cunha VR Da       Brazil         NCEP-ATP III        2012   ≥18          56.8       Both     283                 50                                      233         39.2                    \[[@pone.0170361.ref053]\]

  Goshayeshi L      Iran           NCEP-ATP III        2012   \-           45.5       Both     120                 14                                      106         45.2                    \[[@pone.0170361.ref021]\]

  Bkaer JF          USA            IDF                 2012   18--85       49.5       Both     499                 83                                      416         10.6                    \[[@pone.0170361.ref054]\]

  Crowson CS        USA            NCEP-ATP III        2011   ≥18          58.8       Both     232                 58                                      174         33.0    36.0    32.0    \[[@pone.0170361.ref031]\]

  Sahaberi M        Iran           IDF                 2011   \-           45.5       Both     120                 14                                      106         30.8    28.6    41.5    \[[@pone.0170361.ref055]\]

  Sahaberi M        Iran           NCEP-ATP III        2011   \-           45.5       Both     120                 14                                      106         45.2    28.6    37.7    \[[@pone.0170361.ref055]\]

  Karimi M          Iran           NCEP                2011   ≥18          48.3       Female   92                  \-                                      92          27.2    \-      27.2    \[[@pone.0170361.ref022]\]

  Karimi M          Iran           WHO                 2011   ≥18          48.3       Female   92                  \-                                      92          19.6    \-      19.6    \[[@pone.0170361.ref022]\]

  Mok CC            Hong Kong      JS 2009             2011   ≥18          53.3       Both     699                 133                                     566         20.0                    \[[@pone.0170361.ref056]\]

  Dao HH            Vietnam        IDF                 2010   26--73       56.3       Female   105                 \-                                      105         40.9    \-      40.9    \[[@pone.0170361.ref057]\]

  Dao HH            Vietnam        NCEP-ATP III 2004   2010   26--73       56.3       Female   105                 \-                                      105         32.4    \-      32.4    \[[@pone.0170361.ref057]\]

  Dao HH            Vietnam        NCEP-ATP III 2001   2010   26--73       56.3       Female   105                 \-                                      105         24.7    \-      24.7    \[[@pone.0170361.ref057]\]

  Dao HH            Vietnam        JS 2009             2010   26--73       56.3       Female   105                 \-                                      105         32.4    \-      32.4    \[[@pone.0170361.ref057]\]

  Dao HH            Vietnam        WHO                 2010   26--73       56.3       Female   105                 \-                                      105         19.0    \-      19.0    \[[@pone.0170361.ref057]\]

  Dao HH            Vietnam        EGIR                2010   26--73       56.3       Female   105                 \-                                      105         16.2    \-      16.2    \[[@pone.0170361.ref057]\]

  Raterman H G      Netherlands    NCEP                2010   50--75       62.1       Both     236                 79                                      157         19.9                    \[[@pone.0170361.ref058]\]

  Solomon A         South Africa   NCEP-ATP III        2010   \-           27.2       Both     291                 32                                      259         31.3                    \[[@pone.0170361.ref059]\]

  Solomon B         South Africa   NCEP-ATP III        2010   \-           27.2       Both     335                 65                                      270         20.3                    \[[@pone.0170361.ref059]\]

  Giles J           USA            NCEP-ATP III        2010   45--84       61         Both     131                 51                                      80          36.0                    \[[@pone.0170361.ref060]\]

  Santos MJ         Portugal       ATP III             2010   ≥18          49.2       Female   98                                                          98          25.5                    \[[@pone.0170361.ref061]\]

  Toms TE           UK             IDF                 2009   55.5--69.6   63.1       Both     387                 105                                     282         45.3    52.7    42.6    \[[@pone.0170361.ref025]\]

  Toms TE           UK             NCEP-ATP III 2004   2009   55.5--69.6   63.1       Both     387                 105                                     282         40.1    42.5    39.2    \[[@pone.0170361.ref025]\]

  Toms TE           UK             NCEP-ATP III 2001   2009   55.5--69.6   63.1       Both     387                 105                                     282         38.3    40.0    37.7    \[[@pone.0170361.ref025]\]

  Toms TE           UK             WHO                 2009   55.5--69.6   63.1       Both     387                 105                                     282         19.4    25.5    17.2    \[[@pone.0170361.ref025]\]

  Toms TE           UK             EGIR                2009   55.5--69.6   63.1       Both     387                 105                                     282         12.1    22.6    8.2     \[[@pone.0170361.ref025]\]

  Chung CP          USA            WHO                 2008   ≥18          59         Both     66                  18                                      48          42.0                    \[[@pone.0170361.ref029]\]

  Zonana-Nacach A   Mexico         NCEP-ATP III        2008   \-           42.9       Both     107                                                                     18.7                    \[[@pone.0170361.ref030]\]

  Karvounaris SA    Greece         ATP III             2007   ≥18          63.0       Both     200                 53                                      147         44.0    39.6    45.6    \[[@pone.0170361.ref032]\]

  Montagna G La     Italy          NCEP-ATP III        2007   \-           53.8       Both     45                  3                                       42          55.5                    \[[@pone.0170361.ref062]\]\
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The estimated pooled prevalence, with 95% confidence interval (the diamond below the graph shows the pooled prevalence and the horizontal lines define the reported 95% confidence interval in each study) are presented in graphs by gender and by MetS definition.

Total MetS prevalence in RA patients by gender {#sec012}
----------------------------------------------

Using a random effects model, the estimated worldwide prevalence rate of MetS among RA patients was 30.65% (95% CI: 27.87--33.43) ([Fig 2](#pone.0170361.g002){ref-type="fig"}). In addition, information on the prevalence of MetS by gender was available from 19 studies for males and 30 for females. The prevalence rates among males was 31.94% (95% CI: 24.37--39.51) and for females this was 33.03% (95% CI: 28.09--37.97) (Figs [3](#pone.0170361.g003){ref-type="fig"} and [4](#pone.0170361.g004){ref-type="fig"}).

![Forest plot of MetS prevalence in RA Patients.](pone.0170361.g002){#pone.0170361.g002}

![Forest plot of MetS prevalence among male RA Patients.](pone.0170361.g003){#pone.0170361.g003}

![Forest plot of MetS prevalence among female RA Patients.](pone.0170361.g004){#pone.0170361.g004}

MetS prevalence in RA patients by criteria/definition {#sec013}
-----------------------------------------------------

The pooled MetS prevalence rates for the eight definitions are: **WHO**---19.96% (95% CI: 17.12--22.81), **NCEP/ATP III**---31.55% (95% CI: 27.95--35.15), **IDF**---32.84% (95% CI: 24.98--40.71), **EGIR**---14.32% (95% CI: 10.59--18.05), **ACCE**---24.6% (95% CI: 19.29--30.91), **AHA/NHBI---**31.39% (95% CI: 20.61--42.17), **ATP III**---37.83% (95% CI: 31.05--44.61) and **JS 2009**--27.54 (95% CI: 17.85--37.24) ([Fig 5](#pone.0170361.g005){ref-type="fig"}).

![Forest plot of MetS prevalence among RA Patients by definition/criteria.](pone.0170361.g005){#pone.0170361.g005}

MetS prevalence in rheumatoid arthritis patients by MetS component {#sec014}
------------------------------------------------------------------

The MetS components of FBS, HDL-C, BP, Triglyceride and Waist Circumstance (WC) were reported by 26, 22, 29, 19 and 24 studies, respectively. The pooled MetS prevalence rates, by component, were: **FBS**---19.47% (95% CI: 15.69--23.25), **HDL**---41.78% (95% CI: 28.73--54.84), **BP**---48.65% (95% CI: 41.03--56.26), **Triglyceride**---28.43% (95% CI: 22.3--34.57) and **WC**---52.63 (95% CI: 43.76--61.5) (S 1--5 Appendix).

Risk of MetS in rheumatoid arthritis patients by criteria/definition {#sec015}
--------------------------------------------------------------------

In this section the prevalence of MetS in RA patients and among healthy controls were compared ([Table 3](#pone.0170361.t003){ref-type="table"}). The pooled estimates identified a significant positive association between rheumatoid arthritis and the risk of MetS (OR = 1.44; 95% CI: 1.20--1.74). The odds ratios for MetS in rheumatoid arthritis patients, according to the definition used, were: **WHO**---OR = 1.45 (95% CI: 0.9--2.33), **NCEP/ATP III**---OR = 1.52 (95% CI: 1.12--2.06), **IDF**---OR = 1.52 (95% CI: 0.84--2.77), **EGIR**---OR = 1.65 (95% CI: 0.95--2.87), **ACCE**---OR = 4.09 (95% CI: 2.03--8.25), **AHA/NHBI**---OR = 0.7 (95% CI: 0.27--1.76), **ATP III**---OR = 1.22 (95% CI: 0.71--2.1), and **JS 2009**---OR = 1.58 (95% CI: 0.84--2.94) ([Fig 6](#pone.0170361.g006){ref-type="fig"}).

![Forest plot of MetS risk among RA patients by definition/criteria.](pone.0170361.g006){#pone.0170361.g006}
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###### Worldwide prevalence (95% CI) of metabolic syndrome in rheumatoid arthritis patients compared to healthy controls.

![](pone.0170361.t003){#pone.0170361.t003g}

  First Author      Country     Criteria       DOP    Gender   N. RA Patients   N. Healthy Controls   Reference                                                                      
  ----------------- ----------- -------------- ------ -------- ---------------- --------------------- ----------- ----- ----- ------- ------ -------- ------ ------- ------- ------- ----------------------------
  Lee SH            Korea       AHA/NHLBI      2016   Both     63.6             \-                    110         488   598   36.45   58.4   \-       8114   11181   19295   34.45   \[[@pone.0170361.ref037]\]
  Muller R          Estonia     NCEP-ATP III   2016   Both     51.6             \-                    66          25    91    35.16   51.5   \-       75     198     273     34.06   \[[@pone.0170361.ref033]\]
  Dihingia P        India       NCEP-ATP III   2016   Both     41.5             \-                    6           66    72    16.66   \-     \-       \-     \-      72      6.94    \[[@pone.0170361.ref039]\]
  Parra-Salcedo F   Mexico      AHA/NHLBI      2015   Both     38.1             \-                    18          142   160   28.12   38.0   \-       18     142     160     4.81    \[[@pone.0170361.ref043]\]
  Parra-Salcedo F   Mexico      IDF            2015   Both     38.1             \-                    18          142   160   18.12   38.0   \-       18     142     160     4.18    \[[@pone.0170361.ref043]\]
  Parra-Salcedo F   Mexico      NCEP-ATP III   2015   Both     38.1             \-                    18          142   160   23.75   38.0   \-       18     142     160     4.31    \[[@pone.0170361.ref043]\]
  Bilecik NA        Turkey      IDF            2014   Female   52.0             24--65                0           100   100   33.0    51.0   27--65   0      100     100     44.0    \[[@pone.0170361.ref044]\]
  Bilecik NA        Turkey      NCEP-ATP III   2014   Female   52.0             24--65                0           100   100   27.0    51.0   27--65   0      100     100     28.0    \[[@pone.0170361.ref044]\]
  Özmen M           Turkey      NCEP-ATP III   2014   Both     51.0             \-                    15          37    52    17.30   48.0   \-       9      21      30      6.60    \[[@pone.0170361.ref045]\]
  Özmen M           Turkey      WHO            2014   Both     51.0             \-                    15          37    52    28.84   48.0   \-       9      21      30      10.0    \[[@pone.0170361.ref045]\]
  Kumar BS          India       IDF            2014   Both     46.0             \-                    6           48    54    31.48   45.4   \-       6      48      54      24.07   \[[@pone.0170361.ref046]\]
  Kumar BS          India       NCEP-ATP III   2014   Both     46.0             \-                    6           48    54    29.62   45.4   \-       6      48      54      22.22   \[[@pone.0170361.ref046]\]
  Abourazzak FE     Morocco     IDF            2014   Both     49.0             \-                    22          157   179   30.72   51.0   \-       23     126     149     5.36    \[[@pone.0170361.ref026]\]
  Abourazzak FE     Morocco     NCEP-ATP III   2014   Both     49.0             \-                    22          157   179   29.05   51.0   \-       23     126     149     5.36    \[[@pone.0170361.ref026]\]
  Abourazzak FE     Morocco     AACE 2003      2014   Both     49.0             \-                    22          157   179   24.58   51.0   \-       23     126     149     7.38    \[[@pone.0170361.ref026]\]
  Salinas MJH       Argentina   ATP III        2013   Both     55.5             \-                    69          340   409   30.31   57.3   \-       103    521     624     39.90   \[[@pone.0170361.ref047]\]
  Salinas MJH       Argentina   IDF            2013   Both     55.5             \-                    69          340   409   35.45   57.3   \-       103    521     624     40.54   \[[@pone.0170361.ref047]\]
  Chung CP          Usa         NCEP-ATP III   2008   Both     59.0             43--59                18          48    66    42.42   52.0   44--58   30     55      85      22.35   \[[@pone.0170361.ref029]\]
  Dao HH            Vietnam     WHO            2010   Female   56.3             26--73                0           105   105   19.04   55.7   25--72   56     49      105     12.35   \[[@pone.0170361.ref057]\]
  Dao HH            Vietnam     IDF            2010   Female   56.3             26--73                0           105   105   40.95   55.7   25--72   56     49      105     22.85   \[[@pone.0170361.ref057]\]
  Dao HH            Vietnam     NCEP-ATP III   2010   Female   56.3             26--73                0           105   105   24.76   55.7   25--72   56     49      105     14.28   \[[@pone.0170361.ref057]\]
  Dao HH            Vietnam     NCEP-ATP III   2010   Female   56.3             26--73                0           105   105   32.38   55.7   25--72   56     49      105     18.09   \[[@pone.0170361.ref057]\]
  Dao HH            Vietnam     EGIR           2010   Female   56.3             26--73                0           105   105   16.19   55.7   25--72   56     49      105     10.47   \[[@pone.0170361.ref057]\]
  Dao HH            Vietnam     JS2009         2010   Female   56.3             26--73                0           105   105   32.38   55.7   25--72   56     49      105     18.09   \[[@pone.0170361.ref057]\]
  Karimi M          Iran        NCEP-ATP III   2011   Both     48.3             \-                    \-          \-    92    27.17   42.2   \-       \-     \-      96      35.41   \[[@pone.0170361.ref022]\]
  Rostam S          Morocco     WHO            2013   Both     49.0             \-                    10          110   120   20.00   48.5   \-       10     90      100     14.00   \[[@pone.0170361.ref049]\]
  Rostam S          Morocco     IDF            2013   Both     49.0             \-                    10          110   120   48.60   48.5   \-       10     90      100     23.00   \[[@pone.0170361.ref049]\]
  Rostam S          Morocco     NCEP-ATP III   2013   Both     49.0             \-                    10          110   120   24.16   48.5   \-       10     90      100     16.00   \[[@pone.0170361.ref049]\]
  Rostam S          Morocco     NCEP-ATP III   2013   Both     49.0             \-                    10          110   120   32.50   48.5   \-       10     90      100     18.0    \[[@pone.0170361.ref049]\]
  Rostam S          Morocco     EGIR           2013   Both     49.0             \-                    10          110   120   18.33   48.5   \-       10     90      100     12.00   \[[@pone.0170361.ref049]\]
  Rostam S          Morocco     JS2009         2013   Both     49.0             \-                    10          110   120   32.50   48.5   \-       10     90      100     18.0    \[[@pone.0170361.ref049]\]
  Crowson CS        Usa         NCEP-ATP III   2011   Both     58.8             \-                    58          174   232   32.75   63.9   \-       560    681     1241    25.46   \[[@pone.0170361.ref031]\]
  Cunha VR da       Brazil      NCEP-ATP III   2012   Both     56.8             \-                    50          233   283   39.22   44.5   \-       34     192     226     19.46   \[[@pone.0170361.ref053]\]
  Giles JT          Usa         NCEP-ATP III   2010   Both     61.0             \-                    51          80    131   35.87   63.0   \-       70     51      121     25.61   \[[@pone.0170361.ref060]\]
  Sahebari M        Iran        NCEP-ATP III   2011   Both     45.5             \-                    14          106   120   45.0    45.6   \-       69     431     500     53.8    \[[@pone.0170361.ref055]\]
  Sahebari M        Iran        IDF            2011   Both     45.5             \-                    14          106   120   30.83   45.6   \-       69     431     500     34.2    \[[@pone.0170361.ref055]\]
  Karakoc M         Turkey      IDF            2012   Both     49.7             \-                    7           47    54    42.59   47.0   \-       43     9       52      9.61    \[[@pone.0170361.ref051]\]
  Santos MJ         Portugal    ATP III        2010   Female   49.2             \-                    0           98    98    24.48   47.7   \-       0      102     102     15.68   \[[@pone.0170361.ref061]\]
  Mok CC            Hong Kong   JS2009         2011   Both     53.3             \-                    133         566   699   19.59   52.9   \-       266    1132    1398    19.88   \[[@pone.0170361.ref056]\]

Publication bias {#sec016}
----------------

In order to assess publication bias in relation to the OR for MetS and RA, funnel plots and Begg\'s correlation were used. These found no evidence of any publication bias ([Fig 7](#pone.0170361.g007){ref-type="fig"}).

![Funnel plot of MetS risk among RA Patients by definition/criteria.](pone.0170361.g007){#pone.0170361.g007}

Meta-regression {#sec017}
---------------

To assess the sources of heterogeneity, four variables were included in a univariable meta-regression. Our results indicated that the study date (P = 0.60) and country (P = 0.38) were not responsible for the heterogeneity in the ORs for MetS in RA patients, compared to healthy controls, but mean age (P = 0.03) and diagnostic criteria (P = 0.04) could be considered sources of heterogeneity. Hence, subgroup analysis was undertaken based upon the diagnostic criteria.

Discussion {#sec018}
==========

The present study found a MetS prevalence of 30.65% among RA patients, but this rate ranged from 14.32% to 37.83%, depending upon the MetS definition used. The relatively high degree of variability in MetS prevalence, according to the MetS definition used, is clearly a substantial issue that permeates the literature on this topic. For example, research in Asia has reported the prevalence of MetS to be 45.2% among RA patients using the NCEP-ATP III criteria \[[@pone.0170361.ref021]\] and 19.6% when using the WHO definition\[[@pone.0170361.ref022]\]. In Europe the prevalence rates reported, according to criteria used were: AHA (27.4%), IDF (35.2%), IDF-AHA (37.2%) and NCEP-ATP III (23.0%)\[[@pone.0170361.ref023]\]. Furthermore, based on the NCE-P-ATP III criteria, Oliveira et al. found that the prevalence of MetS among RA patients in South American was 51.4%, but using the IDF criteria this proportion was 53.4% \[[@pone.0170361.ref024]\]. Much larger differences have been reported in research from the UK, with MetS prevalence ranging from 8.2% to 42.6% \[[@pone.0170361.ref025]\], depending upon the definition used. Moreover, in a cross-sectional study which used three definitions (NCEP-ATP III, IDF and AACE) the prevalence of MetS in RA patients varied from 24.6 to 30.7% \[[@pone.0170361.ref026]\]. Finally, the results of a case- control study in 2013 showed that the frequency of MetS in RA patients and the control group were 30% versus 39% (respectively) when using the ATP III definition and 35% versus 40% (respectively) when using the IDF \[[@pone.0170361.ref027]\] definition.

Therefore, it appears that some of the variation in the prevalence reported are to do with i) a lack of definition clarity, with many different criteria in the existing definitions, ii) different and multiple phenotypes included in each definition of MetS, and iii) the lack of consistency in the number of components required by each definition.

However, prevalence rates also vary widely even when comparing studies that have used the same criteria. For example, using the NCE/ATP definition, Dessein et al. reported a MetS prevalence of 19% among 74 RA patients \[[@pone.0170361.ref028]\], while a separate study using the same definition reported a prevalence rate of 42% in those with long standing RA and 30% in those recently diagnosed with RA\[[@pone.0170361.ref029]\]. Further, in a study of 107 female RA patients a MetS prevalence of 18.7% \[[@pone.0170361.ref030]\] was reported, but using the same definition Crowson et al. reported the prevalence to be 33%\[[@pone.0170361.ref031]\]. Therefore, it is likely that other factors related to the characteristics of the study population, such as: genetic, ethnic, cultural, demographic, socioeconomic and clinical factors, also affect the prevalence. Thus, studies conducted using different populations are critical in order to identify other factors related to MetS.

In this study the risk of MetS in RA patients was 45% higher than that in the healthy control group (OR = 1.45; 95% CI: 1.20--1.75). The OR found in the present study is considerably higher than that reported in a meta-analysis of 12 studies in 2013, which reported an OR of 1.24 (95% CI, 1.03--1.50) \[[@pone.0170361.ref011]\]. Furthermore, Karvounaris et al. found prevalence of MetS to be similar in RA patients (44%) to their control population (41%), but they also found a relationship between disease activity and the presence of MetS \[[@pone.0170361.ref032]\]. It is also worth mentioning that several studies have not reported any association between RA and MetS \[[@pone.0170361.ref033], [@pone.0170361.ref034]\].

When we assessed the individual components of MetS (FBS, HDL, BP, Triglyceride, WC), a high WC had the highest prevalence, while the lowest prevalence was high FBS. These findings are consistent with a cross-sectional study by Zafar et al., which found that high FBS (21.9%) was the least prevalent component, while a high WC (46.1%) was the most prevalent component\[[@pone.0170361.ref035]\]. Furthermore, a study of 200 rheumatoid arthritis outpatients reported that the prevalence of a high WC was 74.8% in female patients and 60.4% in male patients, while the prevalence of high FBS were 30.6% and 26.4% in female and male patients, respectively \[[@pone.0170361.ref032]\]. In another study, blood pressure, hypoglycemia and HDL had prevalence's of 35.9%, 22.95 and 68.9%, respectively \[[@pone.0170361.ref036]\]. Therefore, it seems that in most studies a high WC is the most prevalent MetS component and targeting preventative measures at this may considerably reduce the risk of developing MetS.

Advantages {#sec019}
==========

The present study has a number of advantages over the previous meta-analysis, including: 1) All of the published studies were included in this meta-analysis. 2) The prevalence of metabolic syndrome was investigated in RA patients from across the world. 3) This study reported the prevalence of MetS in RA patients based upon eight separate definitions. 4) This paper included both comparative cross-sectional and cross-sectional studies. 5) The odds ratio for metabolic syndrome was pooled across a large number of studies.

Limitations {#sec020}
===========

1\) Several countries have not assessed the prevalence of MetS in RA patients and therefore data from those countries could not be presented in this study. 2) The crude (unadjusted) odds ratio for MetS in RA patients was reported, as different studies used different set(s) of confounders.

Conclusion {#sec021}
==========

The prevalence of MetS in RA patients was relatively high, but did not vary significantly by gender. According to the high prevalence of MetS in RA patients and the high risk of it, monitoring and testing for metabolic syndrome in these patients is clearly recommended. As the most important component of metabolic syndrome was found to be a high WC, it is clearly important to pay more attention to patient nutrition and weight loss. Finally, mean age and the diagnostic criteria used to diagnose MetS were identified as sources of heterogeneity in the estimated risk of MetS.
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